Market Place
Sourcing Support
Phathom Submits Citizen Petition To FDA For Voquezna Listings
11 Dec 2024 //
GLOBENEWSWIRE
Phathom Pharma Reports Q3 2024 Financial Results & Updates
07 Nov 2024 //
GLOBENEWSWIRE
Phathom Pharmaceuticals to Participate in Investor Conferences
04 Nov 2024 //
GLOBENEWSWIRE
Phathom Pharma to Share Q3 2024 Financial Results on Nov. 7
28 Oct 2024 //
#N/A
Phathom Pharmaceuticals to Share VOQUEZNA® Data at ACG 2024
27 Oct 2024 //
GLOBENEWSWIRE
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
29 Aug 2024 //
GLOBENEWSWIRE
Phathom Pharmaceuticals Prices $130M Stock And Warrant Offering
19 Aug 2024 //
GLOBENEWSWIRE
Phathom Pharma Reports Q2 2024 Results And Provides Business Update
08 Aug 2024 //
GLOBENEWSWIRE
Phathom`s VOQUEZNA® Added To CVS Caremark Commercial Formularies
30 Jul 2024 //
GLOBENEWSWIRE
Phathom To Report Q2 2024 Results On August 8, 2024
29 Jul 2024 //
GLOBENEWSWIRE
FDA Approves Phathom`s VOQUEZNA For Non-Erosive GERD Heartburn Relief
18 Jul 2024 //
GLOBENEWSWIRE
Phathom To Present VOQUEZNA Data At DDW 2024 Annual Meeting
15 May 2024 //
GLOBENEWSWIRE
Phathom Pharma Q1 2024 Financials And Business Update
09 May 2024 //
GLOBENEWSWIRE
Phathom Pharma Q1 2024 Results & Business Update on May 9
29 Apr 2024 //
GLOBENEWSWIRE
Phathom to Participate in the 23rd Annual Needham Virtual Healthcare Conference
03 Apr 2024 //
GLOBENEWSWIRE
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign
26 Mar 2024 //
GLOBENEWSWIRE
Phathom’s first campaign for acid blocker Voquezna is latest to use telehealth
26 Mar 2024 //
ENDPTS
Phathom Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
26 Mar 2024 //
PR NEWSWIRE
Phathom Reports Fourth Quarter and Full Year 2023 Financial Results
07 Mar 2024 //
GLOBENEWSWIRE
Phathom to Report Fourth Quarter and Full Year 2023 Financial Results
29 Feb 2024 //
GLOBENEWSWIRE
Phathom Pharma to Report Fourth Quarter and Full Year 2023 Financial Results
29 Feb 2024 //
PRESS RELEASE
Insider Traders Lose US$55k As Phathom Pharmaceuticals Drops
14 Feb 2024 //
SIMPLYWALL
Phathom Pharmaceuticals Announces VOQUEZNA (vonoprazan) Tablets for Erosive GERD
13 Feb 2024 //
GLOBENEWSWIRE
Phathom to Present at the Guggenheim Healthcare Talks 6th Annual Conference
31 Jan 2024 //
GLOBENEWSWIRE
Phathom Announces Expansion of Existing Loan with Hercules Capital
14 Dec 2023 //
GLOBENEWSWIRE
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA
06 Dec 2023 //
GLOBENEWSWIRE
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA
28 Nov 2023 //
GLOBENEWSWIRE
Phathom Pharmaceuticals Reports Third Quarter 2023 Results
09 Nov 2023 //
GLOBENEWSWIRE
US approves Phathom`s Voquezna for erosive GERD
02 Nov 2023 //
GLOBENEWSWIRE
Phathom Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA
30 Oct 2023 //
GLOBENEWSWIRE
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
25 Oct 2023 //
GLOBENEWSWIRE
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
26 Sep 2023 //
GLOBENEWSWIRE
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
05 Sep 2023 //
GLOBENEWSWIRE
Phathom Announces Submission of Data in Support of Erosive GERD NDA
21 Aug 2023 //
GLOBENEWSWIRE
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
10 Aug 2023 //
GLOBENEWSWIRE
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
01 Jun 2023 //
GLOBENEWSWIRE
Phathom Pharm resubmits NDA for acid blocker, bags $130M+ from offering
24 May 2023 //
ENDPTS
Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA
23 May 2023 //
GLOBENEWSWIRE
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock
23 May 2023 //
GLOBENEWSWIRE
Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
23 May 2023 //
GLOBENEWSWIRE
Phathom Pharmaceuticals Reports First Quarter 2023 Results
10 May 2023 //
GLOBENEWSWIRE
Phathom Pharmaceuticals Presents New Data at Digestive Disease Week (DDW) 2023
09 May 2023 //
GLOBENEWSWIRE
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
12 Apr 2023 //
GLOBENEWSWIRE
Phathom Pharmaceuticals Shares Rise 6% After Feedback From FDA
04 Apr 2023 //
MORNINGSTAR
Phathom Announces Regulatory Update and Plans for 2023 Erosive Esophagitis
04 Apr 2023 //
GLOBENEWSWIRE
Phathom to resubmit applications for Voquezna in coming months
04 Apr 2023 //
FIERCE PHARMA
Phathom Reports Fourth Quarter and Full Year 2022 Financial Results
28 Feb 2023 //
GLOBENEWSWIRE
Phathom Faces Another Delay with H. pylori, Esophagitis Drugs
11 Feb 2023 //
BIOSPACE
Nearing FDA approval anniversary, Phathom gets bad news on Voquezna impurities
10 Feb 2023 //
FIERCE PHARMA
Phathom Pharma Shares Fall After Formal FDA Request For Vonoprazan Data
10 Feb 2023 //
FINANCE YAHOO
Phathom Pharmaceuticals Provides Regulatory Updates
09 Feb 2023 //
GLOBENEWSWIRE
Phathom Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial
08 Jan 2023 //
PRESS RELEASE
Phathom Provides Update on New Drug Application Review of Vonoprazan
03 Jan 2023 //
GLOBENEWSWIRE
Phathom Reports 3Q 2022 Financial Results and Provides Business Updates
08 Nov 2022 //
GLOBENEWSWIRE
Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare
03 Nov 2022 //
GLOBENEWSWIRE
Phathom Pharma Announces Placement of the Remaining $40 Million
01 Nov 2022 //
GLOBENEWSWIRE
Evonik and Phathom partner to produce novel acid-blocker vonoprazan
24 Oct 2022 //
PRESS RELEASE
Phathom Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily
24 Oct 2022 //
GLOBENEWSWIRE
Phathom Pharma to Present Latest Data on Vonoprazan at ACG
18 Oct 2022 //
GLOBENEWSWIRE
Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors
26 Sep 2022 //
GLOBENEWSWIRE
